Pivotal Phase 3 study results for CG Oncology's cretostimogene in high-risk bladder cancer published in The Lancet Oncology

CG Oncology announced the publication of pivotal Phase 3 BOND-003 Cohort C study results in The Lancet Oncology. The data reinforce durable responses, bladder preservation, and a low rate of disease progression for cretostimogene as a monotherapy in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.